Friday 5-16-2014 Gilead Sciences (GILD) $GILD opened at

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2014 at 12:56 PM

Friday 5-16-2014 Gilead Sciences (GILD) $GILD opened at 80.30 hitting the high price of 80.84 and a day low of 79.22 with a total volume of 10,525,700. GILD had a previous close of 80.10 and has been seeing an average volume of 16,749,580.

Overall Average: 72% Buy

Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!

IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 2 hrs 4 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)

Can CVS Overcome the Drug Poised to "Break the Country?"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Consider the following quotes: "What they have done with this particular drug will break the country." "We expect the impact to be minimal for this year." These two quotes, the first from Express Scripts ' chief medical officer Steven... (full story)

Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress. (full story)

Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin). (full story)

Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study. (full story)

Midday Glance: Biotechnology companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)

XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 10:50AM CDT
XenoPort, Inc. (XNPT) announced a deal with Reckitt Benckiser Pharmaceuticals for the development and commercialization of XenoPort's arbaclofen placarbil. (full story)

Early Glance: Biotechnology companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 8:46AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, with shares rising over 19% on the day. (full story)

Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,... (full story)

Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 7:44AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session as the company saw its shares surge 16% on the day. (full story)

Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors... (full story)

Incyte to Collaborate with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:30PM CDT
Incyte Corporation (INCY) inked a deal with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). (full story)

Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study. (full story)

Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S. (full story)

Progenics' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:10AM CDT
Progenics Pharmaceuticals, Inc.'s (PGNX) loss narrows in the first quarter of 2014. (full story)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Major Lawsuit Amidst Market Turmoil

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...

Jollibee and DreamWorks Unite for Cultural Celebration

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Austin PostalAnnex Changes Hands After 19 Years

A Seamless Transition in Austin's PostalAnnex Legacy You know when a business digs its roots deep, becoming more than just a place but a part of the community fabric? That's what’s playing out at the PostalAnnex on W Parmer Lane, Austin. After nearly two decades, this battered yet steadfast hub of office and shipping services is swapping hands, all in the name of...

Alif Semiconductor Unveils StartKit for Edge AI MCU Fam

Here's some clarity amidst the storm of buzzwords: Alif Semiconductor has rolled out something the market's been howling for—Edge AI that doesn't break the bank. It's less about slick press releases and more about real-world implications. We're talking accessibility with their dirt-cheap, small-form-factor StartKit platform for Ensemble and Balletto microcontrollers....

Spot the Signs: Early Gum Disease Insights from Experts

Why Early Detection of Gum Disease Matters Let's dive right into the crux of things. Gum disease, that sneaky antagonist of oral health, starts unassumingly. You brush, you floss, but those gums might still bleed—ever noticed? Dr. Marian Burgard of Fairport Family Dental has a thing or two to say about this, enlightening us through an insightful piece by HelloNation....

Muscle Car Fever Revs Up in New Global TV Series

Chasing the Dream on Wheels Amid the buzz of New York, there's a roar building up that's hard to ignore. It's a sound that echoes through time, capturing the imagination of petrol heads everywhere—those legendary American muscle cars are back in the limelight. I mean, who hasn't dreamt of launching down a highway in a '69 Ford Mustang? 'The Hunt for Rolling Treasure' is...

India's First Upright Proton Therapy System Unveiled

A Leap Forward in Cancer Care: Proton Therapy Revolution Dang, just when you think you've heard it all in cancer treatment, Fortis Healthcare drops a bombshell: India’s first upright proton therapy system. Boom! This isn't your run-of-the-mill radiation treatment we're talking about here. This is the futuristic flair of the MEVION S250-FIT™, featuring upright...

Drunk Angel Celebrates First Year in Crystal Jewelry

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

BrightPlan's AI-Powered Growth: Series C Fuel

Series C Funding Ignites BrightPlan's Ambitions Ever seen a company that's ready to roll with the punches and come out stronger? That's BrightPlan for you. They're pushing the boundaries again, bagging new capital in this Series C round, steered by the seasoned folks over at ABS Capital Partners. Now, here's the thing: We're talking about a 230% revenue surge over just...

Mandeville Pests: Health Dangers Lurking at Home

Pest Trouble Brewing in Mandeville: A Health Alert There’s a storm brewing in Mandeville, Louisiana, and it's not the kind you can see rolling in on the horizon. We're talking about those sneaky pests going unnoticed in our homes. Folks, these pests aren't just a nuisance; they're ticking time bombs for public health. Take it from J&J Exterminating, who know a thing or...